By Professor Richard Bryan Lock

Conference Posters

Haber M; Karsa M; Connerty P; Karsa A; Spurling D; Pomilio G; Litalien V; Xie J; Cheung LC; Kotecha RS; Chernova O; Gudkov AV; Lock RB; Norris MD; Wei AH; Moujalled D; Somers K, 2026, 'Abstract 3979: Targeting nicotinamide metabolism with NAMPT-inhibitor OT-82 potentiates venetoclax in preclinical models of pediatric and adult acute myeloid leukemia', Vol. 86, pp. 3979 - 3979, http://dx.doi.org/10.1158/1538-7445.am2026-3979

O'Rourke M; Modis L; Harris R; Tasegian A; Azevedo A; Del Barco Barrantes IDBB; Greger L; Gokhale P; Lock R; Connerty P; Davies C; Hooper-Greenhill E; McGarry D; Brown G; Pass M, 2025, 'Amx-883, a potent and selective degrader of BRD9 drives differentiation in acute myeloid leukaemia and shows synergistic efficacy in combination with venetoclax In Vivo and prevents the emergence of resistance to venetoclax in vitro.', Vol. 146, pp. 1489, http://dx.doi.org/10.1182/blood-2025-1489

Karsa M; Connerty P; Karsa A; Spurling D; Pomillio G; Litalien V; Cheung L; Kotecha R; Chernova O; Gudkov A; Lock R; Norris M; Haber M; Wei A; Moujalled D; Somers K, 2025, 'Inhibition of nicotinamide metabolism by the novel NAMPT inhibitor OT-82 potentiates venetoclax in paediatric and adult acute myeloid leukaemia models', Vol. 146, pp. 3282, http://dx.doi.org/10.1182/blood-2025-3282

Lock RB; Kurmasheva R; Evans K; Groff D; Watts B; Krytska K; Smith CM; Key FN; Cofini D; Agoncillo M; Neuhauser S; Stearns TM; Jocoy EL; Kwon JY; Chuang JH; Teicher BA; Gorlick R; Mossé YP; Maris JM; Houghton PJ; Bult CJ; Smith MA, 2025, 'Abstract 7041: The CLK/DYRK inhibitor SM09419 shows potent efficacy across a broad panel of pediatric preclinical xenograft models - A report from the Pediatric Preclinical In Vivo Testing Consortium (PIVOT)', Vol. 85, pp. 7041 - 7041, http://dx.doi.org/10.1158/1538-7445.am2025-7041

Doculara L; Evans K; Gooding JJ; Bayat N; Lock RB, 2024, 'Patient-Specific Circulating Tumor DNA for Monitoring Response to Menin Inhibitor Treatment in Preclinical Models of Infant Leukemia', Switzerland, Vol. 16, pp. 3990, Switzerland, http://dx.doi.org/10.3390/cancers16233990

Lock RB; Evans K; Watts B; Bowman EP; Neuhauser S; Stearns T; Chuang JH; Phillip VM; Jessen KA; Jocoy EL; Bult CJ; Teicher BA; Smith MA, 2024, 'The ROR1 antibody-drug conjugate, MK-2140, enhances the efficacy of established drugs in preclinical models of pediatric acute lymphoblastic leukemia', CA, San Diego, Vol. 84, presented at Annual Meeting of the American-Association-for-Cancer-Research (AACR), CA, San Diego, 05 April 2024 - 10 April 2024, http://dx.doi.org/10.1158/1538-7445.AM2024-1905

Connerty P; Xie J; El-Najjar F; Mao J; Cadiz R; Tax G; Dolman MEM; Jayatilleke N; Mayoh C; Moore AS; Colgan J; Marshall GM; Lock RB, 2024, '269 (PB257): Development of a precision medicine platform for paediatric acute myeloid leukaemia', Vol. 211, pp. 114784, http://dx.doi.org/10.1016/j.ejca.2024.114784

Cheung L; Lock R; Kuek V; Kotecha R, 2024, '3049 – TARGETING BONE MARROW MICROENVIRONMENT FOR TREATMENT OF HIGH-RISK B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA', Vol. 137, pp. 104371, http://dx.doi.org/10.1016/j.exphem.2024.104371

Cheung LC; Trinder S; Hughes A; Mullin B; Rashid S; Yuan J; Xu J; Duncan O; Lock RB; Malinge S; Kuek V; Kotecha RS, 2023, 'Targeting Bone Marrow Microenvironment for Treatment of High-Risk B-Cell Acute Lymphoblastic Leukemia', Vol. 142, pp. 2709, http://dx.doi.org/10.1182/blood-2023-173503

Houghton PJ; Kurmasheva RT; Erickson S; Smith MA; Lock RB; Evans K; Toscan C, 2020, 'Prospective validation of single mouse testing (SMT) by the pediatric preclinical testing consortium (PPTC)', Vol. 138, pp. S18, http://dx.doi.org/10.1016/S0959-8049(20)31111-4

Karsa M; Failes T; Arndt GM; Kees UR; Haber M; Norris MD; Sutton R; Lock RB; Somers K; Henderson MJ, 2018, 'PO-405 Repositioning existing drugs as novel therapeutics for high-risk paediatric leukaemia', Vol. 3, pp. a181, http://dx.doi.org/10.1136/esmoopen-2018-eacr25.431

Tuch B; Wu W; Brands K; Colvin E; Sung J; Williams L; Lock R; Wang R, 2008, 'EARLY HUMAN FETAL PANCREAS AS A THERAPY FOR DIABETES', Vol. 86, pp. 561 - 561, http://dx.doi.org/10.1097/01.tp.0000331028.21911.80

Back to profile page